betway必威登陆网址 (betway.com )学报 ›› 2021, Vol. 42 ›› Issue (6): 457-459.DOI: 10.3969/j.issn.2097-0005.2021.06.017

• 临床研究 • 上一篇    下一篇

盐酸替罗非班治疗进展性脑卒中和短暂性脑缺血发作的临床疗效

马福静   

  1. 山东省巨野县人民医院,山东 菏泽 274900
  • 收稿日期:2020-12-19 出版日期:2021-06-25 发布日期:2021-08-25
  • 作者简介:马福静(1967—),男,山东菏泽人,副主任医师,本科,主要从事临床神经病学工作。E-mail:mafujingab@163.com。

Clinical efficacy of tirofiban hydrochloride in the treatment of progressive stroke and transient ischemic attack

Ma Fujing   

  1. People's Hospital of Juye County,Heze 274900, China
  • Received:2020-12-19 Online:2021-06-25 Published:2021-08-25

摘要: 目的 探讨进展性脑卒中和短暂性脑缺血发作采用盐酸替罗非班治疗的效果。方法 选择进展性脑卒中和短暂性脑缺血发作患者100例,均为巨野县人民医院神经内科2017年6月至2019年6月收治,采用数字表抽取法随机分组,就应用常规方案治疗(对照组,n= 50)与加用盐酸替罗非班治疗(观察组,n=50)后两组患者的凝血功能指标、神经功能评分、药物不良反应率、复发性卒中占比展开对比。结果 两组治疗前,凝血功能指标APTT、PLT、PT、PECAM-1差异无统计学意义(P>0.05);治疗后,APTT、PLT、PT指标均变化不明显,差异无统计学意义(P>0.05);但PECAM-1指标明显高于治疗前,且观察组明显高于对照组,差异具有统计学意义(P<0.05)。两组治疗前,神经功能评分差异无统计学意义(P>0.05),治疗后,神经功能评分均有降低,且观察组有更为明显的降低程度,差异具有统计学意义(P<0.05)。结论 进展性脑卒中和短暂性脑缺血发作在常规治疗基础上,加用盐酸替罗非班,可改善血小板聚集现象,促进神经功能恢复,且未出现严重不良反应,可降低卒中复发风险,应用价值十分突出。

关键词: 进展性脑卒中, 短暂性脑缺血发作, 盐酸替罗非班, 凝血功能指标, 卒中复发

Abstract: Objective: To investigate the value of tirofiban hydrochloride in the treatment of progressive stroke and transient ischemic attack. Methods: 100 patients with Progressive stroke and transient ischemic attack from the Department of Neurology in June 2017 to June 2019 were analyzed, randomized digital table method was used to divide the observation group (control group, n=50) and hydrochloric acid treatment group (observation group,n=50) coagulant function index, nerve function score, the rate of adverse drug reactions, recurrent stroke were detected for comparison. Results: Before the treatment, there was no statistically significant difference between the two groups in coagulation function indexes APTT, PLT, PT and pecam-1 (P<0.05), no significant changes were observed in the APTT, PLT and PT indexes after the treatment (P>0.05); However, the pecam-1 index was significantly higher than that before treatment, and the observation group was significantly higher than that of the control group, with statistically significant differences (P<0.05).There was no difference in neurological function scores between the two groups before treatment (P>0.05). After treatment, the scores were all reduced, and there was a more significant reduction in the observation group, with statistically significant differences (P<0.05). Conclusion: Tirofebanja hydrochloride on the basis of conventional treatment can improve platelet aggregation, promote the recovery of nerve function, and reduce the risk of stroke recurrence without serious adverse reactions for progressive stroke and transient ischemic attack.

Key words: progressive stroke, transient ischemic attack, tirofiban hydrochloride, coagulation function index, recurrence of stroke

中图分类号: